and chronopharmacokinetics of methotrexate in micer	- 泵技术(1.062 mg⋅h⁻¹)及 iv (50 mg⋅kg⁻¹)鉛
modification by feeding schedule.	予丙戊酸钠、并测定 VA 动力学的时间依赖性
Jpn J Pharmacol 1993, <b>62</b> , 373 – 8.	变化。 结果: 血浆 VA 浓度及清除率在稳态时
丙戊酸恒速给药在小鼠体内时间药物动力学及	呈昼夜节律性变化(P(0.01),限定进食时间影
进食条件的影响 · · · · · · · · · · · · · · · · · · ·	啊 VA 动力学的节律, 使峰值位相移动约12
宋建国',大户茂弘,小川惕也 (爱媛大学医学	h. 结论:用药时间是影响 VA 药动学的重要
部药理学教研室、爱媛县791-w.日本国)	因素, 进食条件是 VA 药动学节律的同步因子
目的:研究丙戊酸(VA)药物动力学昼夜节律	之一、
变化及进食条件对节律的影响。 方法:对自由	关键词 丙戊酸;药物动力学;昼夜节律;
进食及限定进食的 ICR 小鼠分别以渗透压微	用药计划表
$\cdots \cdots $	$\sim$
BIBLID: ISSN 0253-9756 Acta Pharmacologica Sinica 🕈	围药理学报 1995 Mari 16 (2); 117-120

### Absorption of indometacin from nasal cavity in rats

HUANG Zhi-Li<sup>1</sup>, KAGOSHIMA Masatoyo<sup>2</sup>, KAGAWA Eiichiro, SHIMADA Hideyo (Department of Clinical Pharmacology, School of Pharmaceutical Sciences, Kitasato University, Tokyo 108, Japan)

AIM: To investigate if identical bioavailability, rapid  $T_{max}$ , and  $C_{max}$  of indometacin (Ind) could be achieved when Ind is administered in rats via intranasal (ina) route. METHODS<sub>1</sub> The pharmacokinetics of Ind solution at a dosage of 3 mg  $\cdot$  kg<sup>-1</sup> was studied after iv, ina, and po in rats using HPLC, **RESULTS:** It showed that the time to peak  $(T_{max})$  of ina Ind 3 mg·kg<sup>-t</sup> solution was 0.08 h, approached that after iv route the peak concentration ( $C_{max}$ ) following ina was 20, 0 mg •  $L^{-1}$ , 2. 4 times higher than po dosing. CONCLUSION: It demonstrated that the ina administration of Ind was superior to poin rats . and that Ind absorption through nasal mucosa was a reasonable approach at lower doses.

.....

<sup>4</sup>Visiting Scholar from Department of Pharmacology, Wannan Medical College, Wuhu 241001, China.

\*Correspondence to KAGOSHIMA Masatoyo PhD.

**KEY WORDS** indomethacin; high pressure liquid chromatography; intranasal administration; pharmacokinetics

Indometacin (indomethacin, Ind) is an anti — inflammatory and analgesic-antipyretic drug in experiments. but produces erosions and ulcers in the gastrointestinal tracts<sup>(1,2)</sup>. Our laboratory showed that index of Ind-induced ulcer was highest in po, then iv, and sc routes. If there is an alternative route of administration through which Ind could be at a lower dose to avoid gastric irritation<sup>(31)</sup>, while at the same time is enough to produce desired pharmacological effects<sup>(31)</sup>? The present study is to investigate if identical bioavailability, rapid  $T_{max}$ , and  $C_{max}$  of Ind could be achieved when Ind is administered in rats via intranasal (ina) route.

Received 1993-12-23 Accepted 1994-08-29

#### MATERIALS AND METHODS

**Chemicals** Ind was from Sigma. Phenacetin (used as an internal standard), acetonitrile, and sodium acetate tribydrate were from Tsukishima Pharmaceutical Co. Kanto Chemical Co. and Wako Pure Chemical Industries, respectively. All other chemicals were of AR.

**Preparation of Ind solution** Ind 50 mg in 3.5 mL of 2.5 % Na<sub>2</sub>CO<sub>3</sub> solution. was mixed with 1.5 mL of HCl 0.5 mol  $\cdot$  L<sup>-1</sup>, and shaken for about 20 min. The pH was adjusted to 7. Using HPLC. Ind in the solution was shown to be stable for at least 48 h. All the solutions were freshly prepared.

In vivo absorption experiments and sample preparation Sprague-Dawley rats  $\delta$ , weighing  $300\pm s$  10 g (n=12), from Japan Laboratory Animal Institute. Tokyo, were fasted for 16 h (water *ad lab*) and equally divided into 3 groups. The surgical procedures to separate nasal cavity from oropharyngeal cavity for *in vivo* nasal administration were those described by Hirai *et al*<sup>-5)</sup>, after 30 min, Ind 3 mg·kg<sup>-1</sup> within 0.1 mL of volume was injected into the nasal cavity by a microsyringe attached to a soft and blunt medical-grade tubing (0, 12 mm in ID, 0, 25 mm in OD. Dow Corning. USA) through one of the nostrils. An iv bolus injection and *po* of the solution were carried out as controls.

Blood samples (0, 2 mL each), taken from the jugular vein at 0, 5, 10, 20, 30, 45, 60, 90, 120, 180, 240, 360 min following each dose, were collected into beparinized polypropylene tubes (Quality Scientilic Plastics, USA) and centrifuged at  $1000 \times g$  at 4 C for 10 min. The plasma was kept at -80 C until assay.

Plasma 50  $\mu$ L and acetonitrile 100  $\mu$ L were mixed with phenacetin 50  $\mu$ L (10 mg·L<sup>-1</sup>). After 10 min, the precipitated protein was removed by centrifugation (1000 × g, 4 C, 10 min), and about 100  $\mu$ L aliquot of the supernatant was transferred to another polypropylene tube for measuring Ind.

Analytical Apparatus A Model SC-8010 HPLC (Tosoh, Tokyo), equipped with a detector (242 nm), a CCPM pump, and a PP-8010 Chart Recorder, was employed. Separation was performed at 25 C on a stainless-steel column (Nucleosil 120-5C8 4.6 mm × 250 mm, GL Sciences Inc.), Samples were automatically introduced onto the column using an AS-8000 Auto Sampler with a 20  $\mu$ L loop valve.

Mobile phase Acetonitrile . NaAc 0. 1 mol  $\cdot L^{-1}$  buller (55/45 v/v) was used as mobile phase. pH adjusted to 4.6 by dropwise addition of HAc. The llow rate was 1.0 mL  $\cdot min^{-1}$ .

Internal standard Phenacetin 1 mg was dissolved in 100 mL of acetonitrile to obtain a 10 mg  $\cdot$ L<sup>-1</sup> internal standard.

**Recovery study** For the determination of recovery 5 replicate samples at levels of 1 and 4 mg·L<sup>-1</sup> for Ind. and 1 mg·L<sup>-1</sup> for phenacetin, were spiked in fresh blank heparinized plasma and run through the procedures as decribed in extraction of samples. The absolute peak heights obtained for extracted samples were compared with those of fresh standard lor Ind and phenacetin in mobile phase.

**Calibration curve** Plasma calibration curves were prepared from a solution of Ind (10 mg  $\cdot$  L<sup>-1</sup>, prepared daily from a stock solution of 500 mg  $\cdot$  L<sup>-1</sup> in acetonitrile and stored at 4 C in darkness up to 1 wk) by serial dilution with plasma (0, 05-50 mg  $\cdot$  L<sup>-1</sup>).

Calculations Ind was determined from the calibration curve of concentration vs the peak height ratio ol Ind to phenacetin. Linear regression analysis and interpolation were performed with a Macintosh classic microcomputer, Tokyo. Pharmacokinetic study and statistical analysis were performed with NEC microcomputer. Peak plasma concentration of Ind  $(C_{max})$ and time to peak  $(T_{max})$  were determined by inspection. Plasma elimination half-time  $(T_{1/2})$  of Ind was estimated from the terminal portion of the log plasma concentration-time curves by least square regression analysis on semilogarithmic plots. AUC was calculated by the trapezoidal rule. The AUC from last datum point to t=infinity was estimated by C/beta, where C represented the last measurable plasma concentration and beta (0.693/ $T_{1/2}$ ), the elimination rate constant.

The t test was used for comparison of the data.

#### **RESULTS AND DISCUSSION**

Ind and the internal standard yielded sharp symmetrical peaks under the conditions given in the experiment with retention times of 6.33 and 4.47 min, resectively (peak a and b in Fig I, B and C). Fig 1A showed a chromatogram of the extract of fresh blank plasma. Fig 1B showed a chromatogram, obtained when the method was applied to spiked plasma containing Ind 4 mg  $\cdot$  L<sup>-1</sup> and the internal standard phenacetin 10 mg  $\cdot$  L<sup>-1</sup>, where no endogenous peaks interfered. Fig IC was a chromatogram of a 50 µL plasma sample 6 h post-dosing from a rat which received Ind 3 mg  $\cdot$  kg<sup>-1</sup> iv. The sample was estimated to contain Ind 5.8 mg  $\cdot$ L<sup>-1</sup>.




Fig 1. Chromatogram of extracts from rat plasma. A) Blank plasma; B) Plasma with indometacin 4 mg  $\cdot L^{-1}$  (peak, 6.33 min) and phenacetin 10 mg  $\cdot L^{-1}$  (peak, 4.47 min); C) Plasma from a rat 6 h after indometacin 3 mg  $\cdot kg^{-1}$  iv containing indometacin 5.8 mg  $\cdot L^{-1}$ .

The linearity was evaluated in plasma in concentrations of 0.05-50 mg  $\cdot$ L<sup>-1</sup>. The calibration curve was best described by a linear equation:  $\hat{Y} = 22.11X \pm 0.17$ , where  $\hat{Y}$  was Ind concentration in mg  $\cdot$ L<sup>-1</sup>, and X was peak height ratio of Ind to phenacetin. A correlation coeffecient of 0.999±0.003 (n=8, P<0.01) was obtained, indicating a high degree of linearty.

The recovery of Ind and the internal standard were  $93 \pm 0.98\%$  and  $89 \pm 0.82\%$ , respectively. (Tab I)

The minimal concentration that could be accurately measured was 20  $\mu$ g·L<sup>-1</sup>(signal-to-noise ratio = 5) with 50  $\mu$ L plasma sample.

Tab 1. Recovery of indometacin and phenacetin from rat plasma. n = 5,  $\bar{x} \pm s$ .

Drug Amoun 50 µL	t added to . plasma	Amount recovered	Recovery
Indometacin	 1 μg	0.94 µg	$94.00 \pm 0.40$
	$4 \ \mu g$	3.68 $\mu g$	$92.00 \pm 1.16$
Phenacetin	4 µg	3.58 µg	$89.50 \pm 0.82$

The pharmacokinetic parameters of Ind solution 3  $g \cdot L^{-1}$  after *po*, iv and ina administrations were shown in Tab 2.

Tab 2. Pharmacokinetics of Indometacin after 3 routes of administration in rats. n=4,  $\bar{x}\pm s$ . 'P>0.05, 'P<0.01 vs po.

	ìv	po	Nasal
AUC, mg•b•L <sup>-1</sup>	84.9±3.6	71.9±3.1	67.4±2.1°
$C_{\max}$ , mg+L <sup>-1</sup>	36.2±1.2	8.3±0.3	20.0±2.4°
$T_{\text{max}}$ , h $T_{1/2}$ , h	0 3.5±0.3	2.3 $\pm$ 0.1 4.0 $\pm$ 0.3	0.08° 3.8±0.3°

The mean  $T_{max}$  after ina was shorter than that after *po* and was approaching that after iv, but the  $T_{max}$  after *po* was 2.3 h.

The  $C_{\text{max}}$  after po was much lower than those following ina and iv, the ina reached the maximum at a concentration of 20.0 mg·L<sup>-1</sup>, while po route did so at 8.3 mg·L<sup>-1</sup>.

 $T_{1/2}$  of po route was 4.0 h, much longer than those of iv and ina dosings.

AUC after ina was close to that after po dosing (P > 0.05). It is suggested that Ind easily passes through both gastrointestinal tract and nasal mucosa to the systemic circulation because of its high lipophylic property.

The plasma concentration after ina reached its maximum within 0.08 h, but the plasma concentration after oral dosing did not rise so quickly or so high. (Fig 2.)




Fig 2. Plasma concentration of indometacin after 3 routes of administration of  $3 \text{ mg} \cdot \text{kg}^{-1}$  in rats.

In conclusion, Ind could easily pass through the nasal mucosa and enter the systemic circulation, nasal absorption was rapid and peak concentration was high, compared with those following po. Therefore, the ina administration may be useful for rapid onset of its pharmacological effects. A study is underway on the rapid onset of pharmacological effects both in animals and humans.

#### REFERENCES

 Djahanguiri B. The production of acute gastric ulceration by indomethacin in the rat.

Scand J Gastroenterol 1969: 4: 265-7.

2 Lanza FL. Endoscopic studies of gastric and duodenal injury after the use of ibuprofen, aspirin, and other

nonsteroidal anti-inflammatory agents. Am J Med 1984, 77: 19-24.

- 3 Takeuchi K. Ueki S. Okabe S. Importance of gastric motility in the pathogenesis of indomethacin-induced gastric lesions in rats. Dig Dis Sci 1986; 31: 1114-22.
- 4 Paluszezak D, Bianchi A, Chaoui A, Cazin JC, Cazin M, Pharmacological activity, blood and tissue levels of indomethacin after single oral administration of two long-acting forms in the rat.

Methods Find Exp Clin Pharmacol 1989; 11: 73-80.

5 Hirai S, Yashiki T, Mina H. Absorption of drugs from the nasal mucosa of rat. Int J Pharm 1981; 7: 317-25.

## 大鼠鼻腔吸收吲哚美辛 $\mathbb{C}_{\mathbb{C}} \subset \mathbb{C}_{\mathbb{C}}$

黄志力, 虎兒為 正璧, 香川榮一郎, 島田英世 (北里大学药学部临床药理学教室, 东京108, 日本国)

目的,研究吲哚美辛经大鼠鼻腔给药的可行性, 方法:用高效液相色谱仪测定血浆中吲哚 美辛的药浓变化,比较大鼠吲哚美辛3 mg •kg<sup>-1</sup>水溶液经口服、静脉与鼻腔给药的吸收 特点. 结果:鼻腔给药达峰时间为0.08 h,几 乎接近于静脉给药;峰浓度为20.0 mg•L<sup>-1</sup>, 是口服给药的2.4倍.吲哚美辛水溶液鼻腔给 药达峰迅速,峰值浓度高,吸收好. 结论,低 剂量吲哚美辛经鼻腔给药为一合理,可望替代 口服的给药方式.

关 **律** 调 哚 美 辛; 高 效 液 相 色 谱 法; 鼻内给药;药物动力学

Sil - Prilit

# 《中国药理学报》欢迎投稿

《中国药理学报》继续进入国际著名《科学引文索引》SCI及 Current Contents,并且保持引文 率名列入选中国期刊前矛. 继续入选国际药学药理学核心期刊,成为其中唯一中国期刊并保持 排名上升趋势. 作者投稿我刊,能最快地被国际同行检索,获益最大. 为扩大国际交流,更好地 光大发展我国药理事业,欢迎广大作者将您的优秀论文(英文或中文)投寄我刊,